Vogs 0.2 tablets 30’s

Description

Vogs® 0.2 is a medication primarily used for the management of type 2 diabetes. It contains the active ingredient Voglibose, which is an alpha-glucosidase inhibitor. Below are the details of the medication:

Vogs® 0.2 – Key Details

• Active Ingredient: Voglibose (0.2 mg per tablet)
• Class: Alpha-glucosidase inhibitor
• Strength: 0.2 mg per tablet
• Pack Size: Typically comes in a strip of 30 tablets.

Mechanism of Action

Voglibose works by inhibiting the alpha-glucosidase enzymes in the intestines. These enzymes are responsible for breaking down complex carbohydrates into simpler sugars (glucose). By inhibiting these enzymes, Voglibose delays the absorption of glucose from the intestines into the bloodstream, thereby reducing the rise in blood sugar levels after meals.

Indication

• Voglibose is primarily prescribed for type 2 diabetes mellitus.
• It is used when blood sugar levels are not adequately controlled by diet and exercise alone.
• Often prescribed as an adjunct to other antidiabetic medications (e.g., Metformin) to improve overall blood glucose control, particularly after meals.

Dosage

• The standard dose of Vogs® 0.2 is typically one tablet taken at the start of each main meal (usually 2-3 times a day), but the exact dosage should be determined by a healthcare provider based on the individual patient’s needs.
• The dosage may vary depending on the severity of the diabetes and the patient’s response to treatment.

Side Effects

Common side effects include:

• Gastrointestinal issues such as:
  • Flatulence (gas)
  • Diarrhea
  • Abdominal pain or discomfort
  • Nausea
• Rare side effects may include:
  • Hypoglycemia (low blood sugar), especially if combined with other medications that lower blood glucose levels.

Precautions

• Voglibose should not be used in individuals with severe gastrointestinal disorders such as inflammatory bowel disease, obstructions, or intestinal ulcers.
• Caution is required in patients with kidney or liver problems.
• Should not be used in patients with hypersensitivity to Voglibose or any other components of the formulation.

Important Notes

• Voglibose is not intended to be used as a standalone therapy. It is generally part of a broader treatment regimen that includes dietary changes, exercise, and possibly other medications.
• Monitoring of blood glucose levels is crucial during treatment to ensure proper control of blood sugar and to adjust dosages as necessary.
• If a dose is missed, it should be taken with the next meal. Do not double dose to make up for a missed one.

As always, it is essential to consult with a healthcare provider before starting any new medication, including Vogs® 0.2, to ensure it is appropriate for your condition and that any potential interactions with other drugs are managed.